July 23 (Reuters) - Valeant Pharmaceuticals International Inc VRX.TO :
* Reports second quarter 2015 financial results
* Q2 GAAP loss per share $0.15
* Q2 revenue $2.7 billion versus I/B/E/S view $2.54 billion
* Q2 earnings per share view $2.46 -- Thomson Reuters I/B/E/S
* Q2 cash earnings per share $2.73 excluding items
* Qtrly same store sales organic growth was 19%
* Says increasing 2015 total revenue to $10.7 - $11.1 billion up from $10.4 -
$10.6 billion
* Says raising guidance for the remainder of 2015
* Says FY salix revenue expected to be about $1.2 billion
* Says increasing 2015 cash EPS to $11.50 - $11.80 per share
* Says expect same store sales organic growth of above 10% for second half of
2015
* Sees Q3 total revenue $2.6 - $2.8 billion
* Sees Q3 cash EPS $2.60 - $2.70 per share
* FY 2015 earnings per share view $11.10, revenue view $10.48 billion --
Thomson Reuters I/B/E/S
* Q3 earnings per share view $2.87, revenue view $2.75 billion -- Thomson
Reuters I/B/E/S
* Source text for Eikon ID:nPncdhrxk
* Further company coverage VRX.TO